TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06594991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab IV given every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab IV given every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab IV given every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab IV given every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be give every 6 weeks continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be give every 6 weeks continuously
Study: NCT06600386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitement
Description: PEEP after alveolar reruitment maneuvres

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PEEP
Description: PEEP 5 cmH2O
Study: NCT05725837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
Study: NCT04990388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: consists of the same components as the formulation buffer for UX053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion
Study: NCT05725837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
Study: NCT06607016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KJ103 for Injection
Description: Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
Study: NCT04990388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Blocker
Description: participants will receive oral premedication prior to infusion
Study: NCT05743426

Intervention type: OTHER
Intervention: Survey
Description: Patient Reported Outcome (PRO) questionnaire

Intervention type: OTHER
Intervention: Toxicity Assessments
Description: Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
Study: NCT05389618

Intervention type: OTHER
Intervention: Diagnostic Tests
Description: Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)

Intervention type: OTHER
Intervention: Diagnostic Tests
Description: Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
Study: NCT06607016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Hence treatment prevents formation of new anti-GBM antibodies.
Study: NCT05987774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI Modules for Improving Social Conversation
Description: The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers.
Study: NCT06607016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Glucocorticoids inhibit the inflammation process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Description: PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
Study: NCT06510673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet-rich plasma for the heel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High power LASER
Description: High power LASER sessions for the heel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: Shockwave therapy sessions for the heel

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ice application
Description: Ice application for the heel

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham LASER
Description: Sham LASER for the heel
Study: NCT06270862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: Receive mini course on what is resilience and how to use different exercises to be more resilient in life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: Play games that trains attention, memory and planning using the services provided by CogniFit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Play games that trains attention, memory and planning using the services provided by CogniFit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Engage in age-appropriate physical exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: Engage in age-appropriate physical exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social interaction
Description: Engage in social discussion with peers in the group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social interaction
Description: Engage in social discussion with peers in the group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: workshop series
Description: Watch a series of workshops targeting the older adult population.
Study: NCT06607237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DM-28
Description: 1 drop in each eye, 4 to 6 times per day
Study: NCT06605300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (IN-OXT)
Description: Subject assigned to receive intranasal administration of oxytocin (24 IU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Vasopressin (AVP)
Description: Subjects assigned to receive intranasal administration of AVP (20 IU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Subjects assigned to receive intranasal administration of placebo.
Study: NCT06604793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT06607107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX7 combined with Camrelizumab and apatinib
Description: mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
Study: NCT06246656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Expansion
Description: Palatal Expansion using a CAD/CAM appliance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Expansion
Description: Palatal Expansion using a CAD/CAM appliance
Study: NCT05611372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: 1 mg rasagiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline
Study: NCT06616311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency microneedling
Description: The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
Study: NCT06671704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling months 4-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 4 to month 15.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling months 6-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 6 to month 15.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling months 8-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 8 to month 15.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling at months 10-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 10 to month 15.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling at months 12-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 12 to month 15.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling at months 14-15
Description: all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 14 to month 15.
Study: NCT04827732

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy
Description: When feasible it is strongly recommended that radiotherapy begin on a Monday

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy
Description: When feasible it is strongly recommended that radiotherapy begin on a Monday

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy
Description: When feasible it is strongly recommended that radiotherapy begin on a Monday

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Description: -The device that will administer the IMPT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Description: -The device that will administer the IMPT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Description: -The device that will administer the IMPT
Study: NCT04605783

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Travelan®
Description: Travelan® (600mg) taken as 1 sachet twice daily with meals. Product will be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin - To be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
Study: NCT06681389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-201 acetate injection (Part A)
Description: Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered across Part A and Part B
Study: NCT04752696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan
Description: Intravenous infusion
Study: NCT05152901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.3mg) inhaled
Description: Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine (1.3mg)
Description: A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine (4mg)
Description: A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
Study: NCT05490745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills4Parenting+
Description: Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list (nocebo)
Description: Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
Study: NCT06291025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEX-FREE
Description: The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
Study: NCT05859789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kegel exercise
Description: * Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kegel exercise
Description: * Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet regimen for 12 weeks.
Description: kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
Study: NCT05390957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Based Behavioural Therapy - Revised
Description: The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
Study: NCT05241067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (Dose: equal volume saline) + Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Centhaquine
Description: Centhaquine (Dose: 0.01 mg/kg) + Standard of care
Study: NCT04752696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenous infusion
Study: NCT06699212

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 IV infusion, Q3W up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV Infusion, Q3W up to 6 cycles